Psilocybin and psychology: what does the evidence really say?
For someone living with persistent depression, distress after a cancer diagnosis, or a difficult relationship with alcohol, reports about "magic mushrooms" can sound very hopeful. Some headlines suggest that one experience might transform a person's mental health. Others focus on danger or controversy.

The reality is more nuanced. Research into psilocybin-assisted therapy has produced some encouraging results, but it also leaves important questions unanswered. The benefits have usually been studied alongside psychological support, in carefully screened participants and supervised settings. That is very different from taking mushrooms on your own.
A quick clarification first: the mushroom compound discussed here is psilocybin. It is sometimes confused with phycobilin, a group of light-harvesting pigments found in algae and cyanobacteria. The two are unrelated.
This article is educational and is not a recommendation to use psilocybin. Psilocybin is a controlled substance in Australia, with limited exceptions for specified medical and research use. Do not use mushrooms or other psilocybin products to treat yourself, and do not change prescribed medication without speaking to your treating clinician.
Origins
Indigenous knowledge and ceremonial use
Long before psilocybin was studied in laboratories, Indigenous peoples in Mesoamerica used certain mushrooms in healing and spiritual ceremonies. These practices are part of living cultural traditions, not simply an early version of modern clinical treatment.
In the 1950s, American writer R. Gordon Wasson took part in a Mazatec mushroom ceremony in Mexico. His writing brought wide Western attention to practices that Indigenous communities already knew. Swiss chemist Albert Hofmann isolated and identified psilocybin in 1958.
This history deserves care. Science did not begin these traditions, and respectful research means taking questions of cultural recognition, benefit and possible exploitation seriously.
Research, restriction and renewed interest
During the 1960s, researchers explored psychedelics in many settings, including psychotherapy, though the quality and ethics of that work varied. Recreational use, public concern and legal restrictions led to a long decline in research.
Interest returned around the turn of the century. A 2006 study by Griffiths and colleagues examined psilocybin experiences in healthy volunteers, many of whom described them as personally meaningful. It was not a treatment trial, but it helped spark the modern wave of research into depression, distress in serious illness, addiction and other conditions.
Definitions
Psilocybin, psilocin and the brain
Psilocybin is a naturally occurring compound found in certain mushrooms, including the Psilocybe genus. Clinical studies usually use a manufactured, standardised preparation rather than wild mushrooms.
In the body, psilocybin is converted to psilocin, which acts on several brain receptors, particularly the serotonin 2A (5-HT2A) receptor. This activity is closely linked to the psychedelic effects: changes in perception, emotion, thinking and sense of self.
Knowing how a substance acts on a receptor does not fully explain whether, or how, a person benefits. Researchers are still examining the roles of brain effects, the subjective experience, expectations, the therapeutic relationship and support afterwards.
More than a medicine session
Psilocybin-assisted therapy describes a structured approach in which the substance is given in a supervised setting, with psychological preparation and follow-up. A typical research protocol includes:
Assessment: reviewing mental and physical health, medicines, previous treatments, risks and goals.
Preparation: building a therapeutic relationship, explaining what may happen, and discussing consent and support plans.
Supervised administration: a controlled dose in a clinical setting, with trained professionals present and medical monitoring available.
Integration: follow-up conversations to reflect on the experience and what, if anything, to carry into daily life.

The experience is not always pleasant. People may feel calm, connected or moved, but also confused, anxious or frightened. A powerful experience does not guarantee improvement.
Set and setting
Set refers to what a person brings to the experience, such as expectations and mood. Setting refers to the environment, including the people present. Both help explain why a supervised clinical session cannot be equated with unsupervised use.
Usability and concrete examples
Imagine someone with long-standing depression asking their psychologist about a news story on psilocybin. A good first step is not to assume they are a suitable candidate, but to understand what they have tried, what they hope for and what worries them.
In an authorised service or research setting, a psychologist may contribute to assessment, preparation, support during the session and integration, within their training and the service's arrangements. In Australia, psychologists do not prescribe psilocybin.
Illustrative example: long-standing depression
"Alex" has had depression for years and feels discouraged after several treatments gave limited relief. Alex and their psychologist review existing care, and Alex then speaks with a psychiatrist who considers treatment history, health, medicines and risks. If Alex is assessed as suitable for an authorised service, preparation would focus on realistic expectations rather than promising a particular experience. Afterwards, they would reflect together on what arose, including anything upsetting, and continue to monitor symptoms, functioning and safety.
Illustrative example: cancer-related distress
"Sam" is living with cancer and feels overwhelmed by uncertainty. Sam reads about a psilocybin study and asks whether it is available. The psychologist acknowledges the interest, explains that the research is encouraging but that the Australian prescribing pathway covers treatment-resistant depression only, and helps Sam explore established psychological and supportive care with their cancer team.
In both cases, the client's values and choices come first. A psychologist should never pressure someone towards a treatment, tell them what their experience "really means", or treat an intense session as a substitute for ongoing care.
Contemporary research
Depression
Depression has received the most attention. In a small 2021 randomised study, Davis and colleagues found substantial improvements in people with major depression who received psilocybin-assisted therapy, compared with a waiting-list group. Because the comparison was a waiting list, the study could not separate the effect of psilocybin from expectations and extra therapeutic attention.
Also in 2021, Carhart-Harris and colleagues compared psilocybin with the antidepressant escitalopram over six weeks, both with psychological support. Both groups improved, and the difference on the main depression measure was not statistically significant. Some secondary results favoured psilocybin, but the study does not show that psilocybin is superior to escitalopram.
A meta-analysis discussed in the Australian Journal of General Practice reported a standardised mean difference of -0.78 in favour of psilocybin. This is an average difference between groups across studies, not a cure rate or a prediction for any individual, and it carries the limitations of the original studies.
Treatment-resistant depression
An early 2016 feasibility study by Carhart-Harris and colleagues explored psilocybin for treatment-resistant depression. Participants knew they were receiving psilocybin and there was no control group, so it raised questions rather than answering them.
The 2022 trial led by Goodwin and colleagues was larger: 233 people with treatment-resistant depression received one of three psilocybin doses with psychological support. At three weeks, the highest-dose group had a greater reduction in depression than the low-dose group; the middle dose did not show a significant difference. Long-term benefit remained uncertain, and some participants across dose groups experienced suicidal thoughts, self-injury or suicidal behaviour. The trial cannot establish the cause of each event, but it underlines the need for careful assessment and ongoing support.
Distress in people with cancer
Two small 2016 trials, led by Griffiths and by Ross, studied psilocybin with psychological support in people with cancer-related distress. Both reported reductions in depression and anxiety. Their small size and crossover design (participants eventually received both interventions) limit long-term conclusions. These studies do not suggest psilocybin treats cancer itself.
Alcohol use disorder
In a 2022 randomised trial, Bogenschutz and colleagues gave 95 adults with alcohol use disorder either psilocybin or an active comparison medicine (diphenhydramine), with both groups receiving psychotherapy. Over 32 weeks, heavy drinking occurred on 9.7% of days in the psilocybin group versus 23.6% in the comparison group. This is promising, but blinding is difficult when the substances feel different, and further replication is needed.
Smoking cessation
A 2014 pilot by Johnson and colleagues combined psilocybin with cognitive behavioural therapy. Of 15 participants, 80% were biologically verified as abstinent at six months. With no comparison group, the study cannot show that psilocybin caused the result. A later randomised comparison with nicotine patches was also encouraging, though again difficult to blind.
Other areas
Researchers are investigating obsessive-compulsive disorder, bipolar depression and other conditions, but these remain early. "Microdosing" should not be assumed to work like the supervised sessions above; its findings are mixed, and expectations may play a large role.
Limitations and risks

Why the findings need caution
Small, selective studies. Many trials are small and exclude people with complex medical or mental health histories. Participants have not always reflected the diversity of people who might seek care, and uncommon harms are hard to detect.
Blinding. Participants and staff can often guess who received psilocybin because the experience is distinctive. This does not mean benefits are imagined, but it makes the true size of the effect harder to estimate.
What is doing the work? Trials include hours of preparation, supervision and follow-up. It is unclear how much improvement comes from the medicine, the support, expectations or their interaction.
Durability. Some people improve for months; others relapse or do not improve. The best way to maintain benefit is still unknown.
Psychological risks
Psilocybin can bring intense fear, confusion or a frightening loss of control. Some people report difficulties that persist after the effects wear off. Screening and support reduce risk but cannot remove it, and people are vulnerable in an altered state, which makes consent, professional boundaries and follow-up essential.
People with a personal history of psychosis or mania, and sometimes those with a relevant family history, are usually excluded from trials. Psilocybin may worsen psychotic symptoms or trigger mania in vulnerable people.
Physical effects and medicines
Psilocybin can temporarily raise blood pressure and heart rate, and headache, nausea and anxiety have been reported. Never stop an antidepressant or other medicine to pursue psilocybin; talk to your prescriber first.
Suicidal thoughts
Depression itself can involve suicidal thoughts, and some trial participants have experienced suicidal thoughts or behaviour after psilocybin. If you are in immediate danger, call 000 or go to your nearest emergency department. You can also call Lifeline on 13 11 14.
Wild mushrooms and unregulated products
Wild mushrooms are not a substitute for a clinical preparation. Misidentification can be dangerous, and the contents of unregulated products cannot be judged by appearance or marketing. If someone may have eaten a poisonous mushroom, call the Poisons Information Centre on 13 11 26, or 000 if they are seriously unwell.
The legal position in Australia
Since 1 July 2023, the Therapeutic Goods Administration (TGA) has allowed specifically authorised psychiatrists to prescribe psilocybin for treatment-resistant depression under the Authorised Prescriber Scheme. This requires ethics committee review, TGA authorisation and compliance with state or territory rules.
This is a restricted pathway, not legalisation. For that use, psilocybin is a Schedule 8 controlled drug; otherwise it generally remains a Schedule 9 prohibited substance, limited mainly to approved research. The TGA notes that these products are still unapproved medicines, meaning they have not been through its usual evaluation of quality, safety and efficacy.
In the United States, the Food and Drug Administration has granted "breakthrough therapy" designation to some psilocybin programs for depression. This speeds development and review; it is not approval.
Future directions

The next phase of research needs to answer practical as well as biological questions:
Who benefits? Larger, more diverse trials can test whether results apply beyond selected participants.
How long do benefits and harms last? Longer follow-up can clarify relapse, ongoing support needs and rarer adverse effects.
What drives improvement? Better comparison designs can untangle the roles of the drug, the therapy and expectations.
How can care be ethical and accessible? Training, consent, boundaries, cultural respect and cost all matter.
Is the "trip" necessary? Researchers are exploring related compounds designed to work without hallucinogenic effects, though this remains unproven.
A final word
Psilocybin research is genuinely promising, particularly for depression, but it is not a proven cure and it does not help everyone. If you are curious, start with a conversation rather than a decision. A psychologist, GP or psychiatrist can help you consider your circumstances, discuss established treatments, and tell you whether a referral or clinical trial might be relevant. Choosing not to pursue a new treatment is never the same as giving up on recovery.
References
Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 2022.
Carhart-Harris RL, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016.
Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021.
Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry. 2021.
Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022.
Griffiths RR, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning. Psychopharmacology. 2006.
Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol. 2016.
Johnson MW, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014.
Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. J Psychopharmacol. 2016.
Royal Australian College of General Practitioners. Psychedelic-assisted psychotherapy. Australian Journal of General Practice. 2026.
Therapeutic Goods Administration. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. 2023.
Therapeutic Goods Administration. Prescribe MDMA or psilocybine (psychiatrists).




Comments